Estrella Immunopharma hit with Nasdaq $1 bid warning
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Estrella Immunopharma, Inc. (ESLA) reported that on August 17, 2026 it received a Nasdaq notice that its common stock no longer meets the $1.00 minimum bid price requirement, after trading below $1.00 for 30 consecutive business days from July 6 through August 14, 2026. The stock continues to trade on the Nasdaq Capital Market under “ESLA” while the company has 180 calendar days, until February 16, 2027, to regain compliance by having a closing bid of at least $1.00 for at least ten consecutive business days, or longer at Nasdaq’s discretion. Estrella may use tools such as a reverse stock split, which would need to be completed at least ten business days before the compliance deadline, and could receive an additional 180-day period if it meets other Nasdaq listing standards. The company plans to monitor its share price and evaluate options, but states there is no assurance it will regain or maintain compliance.
Positive
- None.
Negative
- Nasdaq notified the company that ESLA shares failed the $1.00 minimum bid price requirement for 30 consecutive business days, creating a risk of delisting after February 16, 2027 if compliance is not regained.
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Key Figures
Minimum Bid Price Requirement: $1.00 per share
Consecutive business days below $1.00: 30 business days
Initial compliance period: 180 calendar days
+5 more
8 metrics
Minimum Bid Price Requirement
$1.00 per share
Required minimum closing bid price for continued listing on The Nasdaq Capital Market
Consecutive business days below $1.00
30 business days
From July 6, 2026 through August 14, 2026 triggering the Nasdaq deficiency notice
Initial compliance period
180 calendar days
Time given to regain minimum bid price compliance, ending February 16, 2027
Consecutive days needed at or above $1.00
10 business days
Minimum period the closing bid must be at least $1.00 to regain compliance
Reverse split timing requirement
10 business days
Any reverse stock split must be completed at least ten business days before the compliance date
Warrant exercise price
$11.50 per share
Exercise price of each whole warrant for one share of common stock
Par value of common stock
$0.0001 per share
Par value of Estrella Immunopharma, Inc. common stock
Potential additional compliance period
180 calendar days
Possible second period if other Nasdaq listing standards are met
Key Terms
Minimum Bid Price Requirement, Nasdaq Capital Market, reverse stock split, market value of publicly held shares, +1 more
5 terms
Minimum Bid Price Requirement market
"the Company no longer complies with the $1.00 minimum bid price requirement"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Capital Market market
"for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2)"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
reverse stock split financial
"If the Company elects to implement a reverse stock split to regain compliance"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Nasdaq deficiency notice did Estrella Immunopharma (ESLA) receive?
Nasdaq notified Estrella that its common stock failed the $1.00 minimum bid price requirement after trading below $1.00 for 30 consecutive business days from July 6 through August 14, 2026, putting its Nasdaq Capital Market listing at risk.
How long does ESLA have to regain Nasdaq minimum bid price compliance?
Estrella has an initial 180-day period, until February 16, 2027, to regain compliance by achieving a closing bid price of at least $1.00 for a minimum of ten consecutive business days, or longer if Nasdaq so requires.
Is Estrella Immunopharma’s (ESLA) stock still trading on Nasdaq?
Yes. The company states the notice has no immediate effect on listing or trading. ESLA common stock continues to trade on the Nasdaq Capital Market, subject to meeting all other continued listing requirements.
What happens if ESLA does not regain Nasdaq bid price compliance by February 16, 2027?
If Estrella does not regain compliance by February 16, 2027 and does not qualify for a further 180-day period, Nasdaq may notify the company that its common stock is subject to delisting, which Estrella could then appeal to a Nasdaq hearings panel.
Can Estrella Immunopharma (ESLA) use a reverse stock split to meet Nasdaq rules?
Yes. The company states it may implement a reverse stock split to help meet the $1.00 minimum bid price requirement, but any such split must be completed no later than ten business days before the February 16, 2027 compliance date.
What listing standards besides bid price must ESLA meet for an extra compliance period?
To receive an additional 180-day compliance period, Estrella would need to meet Nasdaq’s initial listing standards for the Nasdaq Capital Market, including the continued listing requirement for the market value of publicly held shares, other than the minimum bid price requirement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
